期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血小板膜糖蛋白、颈动脉IMT与进展性脑梗死相关性的临床研究 被引量：4

下载PDF
导出
摘要 目的探讨血小板膜糖蛋白、颈动脉内膜中层厚度(IMT)在进展性脑梗死(PIS)发病中的作用。方法174例脑梗死患者分为PIS组78例和非PIS组96例,检测全血血小板膜蛋白PAC-1、CD62P阳性率,同时行颈动脉彩色多普勒超声检查,另选择92例健康体检者作为对照组。结果PIS组PAC-1、CD62P阳性率和颈动脉IMT高于非PIS组(P<0.05),且均高于对照组(P<0.05);PIS组血清PAC-1、CD62P阳性率与颈动脉IMT呈正相关(r=0.654、P<0.01,r=0.721、P<0.01)。结论血小板膜蛋白PAC-1、CD62P阳性率可能是PIS发病机制之一,颈动脉粥样硬化严重程度与PIS发病率相关。
作者 金庆 李润辉 宋春英 张海燕
机构地区 沈阳医学院奉天医院
出处 《山东医药》 CAS 北大核心 2010年第8期100-101,共2页 Shandong Medical Journal
关键词 脑梗塞 血小板膜糖蛋白类 PAC-1 CD62 P 颈动脉内膜中层厚度
分类号 R743.33 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献6

  • 1Belniak-Legiec E, Stelmasiak Z. Blood platelet activation markers in patients with acute cerebral infarction during the earliest stage of the disease-evaluation using flow cytometry methods [ J ]. Neurol Neurochir Pol, 2000,34(5) :853-864.
  • 2Karepov VG, Gur AY, Bova I, et al. Stroke-in-evolution: infarct- inherent mechanisms versus systemic causes [ J ]. Cerebrovasc Dis, 2006,21 ( 1-2 ) :42-46.
  • 3包颖,陈晓虹.血小板膜糖蛋白研究进展及其拮抗剂应用现状[J].中风与神经疾病杂志,2008,25(1):114-115. 被引量：2
  • 4Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation [J]. Atherosclerosis, 1997,128 (2) : 135-138.
  • 5凌锋,焦力群,代表国家"十五"医学攻关脑卒中规范化外科治疗技术推广应用研究课题组.颈动脉内膜剥脱术与支架成形术对颈动脉粥样硬化性狭窄治疗的初步研究[J].中国脑血管病杂志,2006,3(1):4-8. 被引量：60
  • 6O' Rourke F, Dean N, Akhtar N, et al. Current and future concepts in stroke prevention [J]. CMAJ, 2004,170(7):1123-1133.

二级参考文献41

  • 1[1]Jordan WD Jr,Schroeder PT,Fisher WS,et al.A comparison of angioplasty with stenting versus endarterectomy for the treatment of carotid artery stenosis.Ann Vasc Surg,1997,11:2-8.
  • 2[2]Jordan WD Jr,Voellinger DC,Doblar DD,et al.Microemboli detected by transcranial Doppler monitoring in patients during carotid angioplasty versus carotid endarterectomy.Cardiovasc Surg,1999,7:33-38.
  • 3[3]Poppert H,Wolf O,Resch M,et al.Differences in number,size and location of intracranial microembolic lesions after surgical versus endovascular treatment without protection device of carotid artery stenosis.J Neurol,2004,251:1198-1203.
  • 4[4]Mericle RA,Kim SH,Lanzino G,et al.Carotid artery angioplasty and use of stents in high-risk patients with contralateral occlusions.J Neurosurg,1999,90:1031-1036.
  • 5[5]Hobson RW,GoldsteinJE,Jamil Z,et al.Carotid restenosis:operative and endovascular management.J Vasc Surg,1999,29:228-235.
  • 6[6]Aburahma F,Bates MC,Stone PA,et al.Comparative study of operative treatment and percutaneous transluminal angioplasty/stenting for recurrent carotid disease.J Vasc Surg,2001,34:831-838.
  • 7[7]Jordan WD Jr,Alcocer F,Wirthlin DJ,et al.High-risk carotid endarterectomy:challenges for carotid stent protocols.J Vasc Surg,2002,35:16-21.
  • 8[8]Illig KA,Zhang R,Tanski W,et al.Is the rationale for carotid angioplasty and stenting in patients excluded from NASCET/ACAS or eligible for ARCHeR justified.? J Vasc Surg,2003,37:575-581.
  • 9[9]Kasirajan K,Matteson B,Marek JM,et al.Comparison of nonneurological events in high-risk patients treated by carotid angioplasty versus endarterectomy.Am J Surg,2003,185:301-304.
  • 10[10]Bowser N,Bandyk DF,Evans A,et al.Outcome of carotid stent-assisted angioplasty versus open surgical repair of recurrent carotid stenosis.J Vasc Surg,2003,38:432-438.

共引文献59

同被引文献40

引证文献4

二级引证文献14

山东医药
2010年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部